Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q2 FY2012-13 Earnings Presentation
49 slides from Alembic Pharmaceuticals's earnings presentation, September 2012
Slide 1: Investor Presentation
Alembic Pharmaceuticals Limited Investor Presentation September 2012 BSE: Symbol: ALEMPHARM Code: 533573 NSE: Symbol: APLLTD ISIN: INE901L01018 www.alembic-india.com
Slide 2: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 3: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 4: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 5: The Alembic Journey
The Alembic Journey 2003 State-of-the-art 2001 Formulations facility for Starts Regulatory 1972 manufacturing of Markets "Althrocin"- a Cephalosporin C 1971 brand of Erythromycin Erythromycin launched 1961 manufactured for the first Lal Bahadur time in India 1940 Shastri, the then Started Prime mini
Slide 6: The Alembic Journey
The Alembic Journey 2012 - Para IV filed 2011 - Cumulatively - ANVISA 50 ANDAs filed, (21 approved) 2010 approvals - Aggressive and 66 DMFs filed - Azithral sales ANDAs and 2009 Reach INR 1000 million DMFs filing Addressed mark 2007 chronic therapies - Demerger AL-APL through Acquisition of multiple
Slide 7: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 8: Insight - Alembic Overview: Branded Formulations
Insight - Alembic Overview Branded Formulations Revenue of INR 7830 million Ranked 22nd in the Ranked 15th in Well equipped in the domestic market for Indian Formulations Doctors Prescription Formulations Plant the financial year 2011-12 market with a market Universe** located at Baddi, share of 1.7
Slide 9: Insight - Alembic Overview: International Division
Insight - Alembic Overview International Division Business size of Sales in Regulatory 1 US FDA World-class INR 6290 million in the Generics Market of INR 2550 approved R&D and F&D financial year 2011-12 million in the financial year Formulations facility 2011-12 Plant Alliances with leading Robust
Slide 10: Business Portfolio
Business Portfolio R&D BRANDED Alliances API Quality FORMULATIONS Business Synergies INTERNATIONAL Manufacturing GENERICS Efficiency
Slide 11: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 12: Strategic Advantage
Strategic Advantage Alembic Research Centre is Well-developed the first in India to be Infrastructure facility - Information Security Certified 4 US FDA approved plants Highly talented pool of High-end quality / 300 Research Scientists RA structure R&D / F&D / Captive Manufacturing excellence Bio-eq
Slide 13: Manufacturing Infrastructure
Manufacturing Infrastructure Formulations - Generics Branded Formulations API (Regulatory Markets) USFDA, MCC, MHRA, Formulations plant at USFDA, EDQM, TGA, WHO ANVISA, TPD approved Baddi, Himachal Pradesh approved API facility at formulations facility at Panelav Panelav (2 units) and at Karkhadi (1
Slide 14: Manufacturing Infrastructure: Certifications
Manufacturing Infrastructure Certifications
Slide 15: Alembic Research Centre
Alembic Research Centre State-of-the-art Analytical & IPR infrastructure R&D FACILITY F&D CAPABILITIES BIO EQUIVALENCE CENTRE R&D Centre has been Expertise in Drug Deliveries State-of-the-art 90-bedded new recognized by DSIR, and Niche Formulations Bio Centre Govt. of India Well-defined Processes Hi
Slide 16: Research Capabilities
Research Capabilities 50 ANDA Filing ANDAs filed 66 with DMFs Filing DMFs filed 21 approvals 74 in place 55 62 45 53 38 39 28 28 17 19 11 17 14 12 11 11 11 10 10 9 9 8 7 Up to 2008-09 2009-10 2010-11 2011-12 Expected Up to 2008-09 2009-10 2010-11 2011-12 Expected 2007-08 2012-13 2007-08 2012-13
Slide 17: Global Presence
Global Presence 21 ANDA Approvals: Pramipexole Dihydrochloride Tablets Lamotrigine Tablets Famotidine Tablets USP Losartan Potassium Tablets (Para IV) Venlafaxine Hydrochloride Tablets Irbesartan Tablets USP (Para IV) USA / Lithium Carbonate Capsules USP Hydrochlorothiazide Capsules CANADA Metronida
Slide 18: Effective Marketing
Effective Marketing PAN India Marketing and Distribution Network OSTEOFIT ZENOVI Orthopedics Gynecology SPECIA Cardiology Diabetes SUMMIT Urology Cardiology INTENSA ENTERON EYECARE Diabetes Critical Care Gastrology Ophthalmology ALCARE MAXIS OTC & Rural General Focused SPECIALITY PHARMA MEGACARE Gen
Slide 19: Effective Marketing
Effective Marketing PAN India Marketing and Distribution Network GENERICS & NSA VETERINARY OTHER PRODUCT PORTFOLIO
Slide 20: Major Product Portfolio
Major Product Portfolio Top Therapatic Ranking* Other Therapatic Products Area Products Area Azithral Anti Infective 26 Ulgel Antacid and Anti Flatulant Zeet/Bro-Zeet Cough & Cold Althrocin Anti Infective 44 Tellzy Cardiology Roxid Anti Infective 126 Gestofit Gynecology Sharkoferrol Tonic Wikoryl Co
Slide 21: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 22: Growth Drivers
Growth Drivers Branded Formulation Business International Generic Business CAGR INR million CAGR INR million 9 16% % 37 58%% 7830 2550 6930 1890 5840 1020 2009-10 2010-11 2011-12 2009-10 2010-11 2011-12
Slide 23: Growth Drivers: Branded Formulations
Growth Drivers Branded Formulations Enhanced focus on existing branded business Expected Through effective pan-India distribution annual growth network and therapy based marketing and by pushing ahead acute and chronic 15% segments like anti-infectives and cough & cold medications Launch 20-25 new p
Slide 24: Growth Drivers: Domestic Market
Growth Drivers Domestic Market Continued capitalization of Dabur Pharma’s assets Expected The non-oncology business of Dabur annual growth Pharma was acquired in 2007. Further capitalization of its assets will yield a 15% stronger product line. Enter into new therapeutic segment Future indentified t
Slide 25: Growth Drivers: International Generics
Growth Drivers International Generics Superior cost efficiency Expected CAGR of Position Alembic as a cost efficient dependable quality manufacturer 25% Expanded annual production capacity Annual production to increase from 2.6 billion tablets/capsules to 5 billion tablets/capsules
Slide 26: Growth Drivers: International Generic Formulation
Growth Drivers International Generic Formulation ANDA filings and approvals for off-patent drugs Expected CAGR of Over the next five years, products that currently generate more than USD 142 billion 25% In sales are expected to go off-patent. Alembic can tap these opportunities by launching new gene
Slide 27: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 28: Business Strategy & Approach
Business Strategy & Approach Sustainable Vertical High Growth in Business Streams Integration Advanced Markets Retaining and consolidating Vertical integration in R&D Partner in international strong presence in acute and manufacturing of market through alliances therapies in the domestic intermediat
Slide 29: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 30: Financial Highlights – Quarterly
Financial Highlights – Quarterly Consolidated Q II - FY 12-13 INR million Sales Q II / 12-13 Q II / 11-12 Business Share '12 Growth % Formulation Branded Domestic 2,198 1,954 54% 13% Generic & NSA 340 315 8% 8% Branded International 87 120 2% ( 28)% Total 2,625 2,389 64% 10% International Division I
Slide 31: Financial Highlights – Quarterly
Financial Highlights – Quarterly Result Highlight (Consolidated) Q II - FY 12-13 INR million Particulars Q II / 12-13 Q II / 11-12 Growth % Year 2011-12 EBDITA 807 751 7% 2,790 (Before R&D) R&D Expenses 160 146 - 586 EBDITA 647 605 7% 2,204 (Post R&D) PBT 530 450 18% 1,610 PAT 425 380 12% 1,301
Slide 32: Financial Highlights – Half Yearly
Financial Highlights – Half Yearly Consolidated H I - FY 12-13 INR million Sales H I / 12-13 H I / 11-12 Business Share '12 Growth % Formulation Branded Domestic 3.901 3,458 50% 13% Generic & NSA 610 535 8% 14% Branded International 162 234 2% (31)% Total 4,673 4,227 60% 11% International Division I
Slide 33: Financial Highlights – Half Yearly
Financial Highlights – Half Yearly Result Highlight (Consolidated) H I - FY 12-13 INR million Particulars H I / 12-13 H I / 11-12 Growth % Year 2011-12 EBDITA 1469 1,375 7% 2,790 (Before R&D) R&D Expenses 299 267 - 586 EBDITA 1,170 1,108 6% 2,204 (Post R&D) PBT 911 805 13% 1,610 PAT 733 656 12% 1,30
Slide 34: Financial Highlights - Yearly
Financial Highlights - Yearly Comparison 2011-12 and 2010-11 INR million Sales 2011 - 2012 2010 - 2011 Business Share '11 Growth % Formulation Branded Domestic 6,750 5,984 46% 13% Generic & NSA 1,076 950 7% 13% International Branded 567 502 4% 13% Total 8,393 7,436 57% 13% International Division Int
Slide 35: Financial Highlights - Yearly
Financial Highlights - Yearly Result Highlight (Comparison 2011-12 and 2010-11) INR million Particulars 2011-2012 2010-2011 Growth % EBDITA 2,900 2,087 39% (Before R&D) R&D Expenses (incl. CAPEX) 696 484 - EBDITA 2,204 1,603 38% (Post R&D) PBT 1,610 1,069 51% PAT 1,301 854 52%
Slide 36: Revenue Overview: Sales Composition Q II
Revenue Overview Sales Composition Q II – FY 12-13 API Export Export Incentive 14% 1% API Domestic 8% Domestic Branded Formulations International Generics 54% 13% International Branded Formulations 2% Generic & NSA 8%
Slide 37: Revenue Overview: Therapy Based Sales Break up
Revenue Overview Sales Composition Q II – FY 12-13 Therapy Based Sales Break up Anti Infectives 42% Gastrology 17% Domestic Cough & Cold 12% Branded Business Gynecology 9% Cardiology 8% Orthopedics 5% Anti Diabetic 4% Nephrology/Urology 2% Ophthalmology 1%
Slide 38: Revenue Overview: Global Sales Break up
Revenue Overview Sales Composition Q II - 2012 Business Global Sales break up Europe 36% International Generics International International Generics Generics USA / Canada 64%
Slide 39: Revenue Overview: Sales Composition 2011-2012
Revenue Overview Sales Composition 2011 - 2012 API Export Export Incentive 19% 1% API Domestic 6% Domestic Branded Formulations 46% International Generics 17% International Branded Formulations Generic & NSA 4% 7%
Slide 40: Revenue Overview: Therapy Based Sales Break up
Revenue Overview Sales Composition 2011 - 2012 Therapy Based Sales Break up Anti Infectives 43% Gastrology 16% Domestic Cough & Cold 13% Branded Domestic Formulations Gynecology 9% Branded Business Cardiology 8% Orthopedics 5% Anti Diabetic 3% Nephrology/Urology 2% Ophthalmology 1%
Slide 41: Revenue Overview: Global Sales Break up
Revenue Overview Sales Composition 2011- 2012 Global Sales break up Europe 40% International Generics International Generics USA / Canada 60%
Slide 42: R & D Expense
R & D Expense Increased Thrust on Research to create Intellectual Property R&D spend as a % to Sales 4.78% 4.51% 4.30% 4.06% 3.60% 2007-08 2008-09 2009-10 2010-11 2011-12
Slide 43: Financial Snapshot
Financial Snapshot SALES PBIDTA CAGR CAGR 713% % INR million 37 % 21 INR million 14679 2204 12066 1603 11487 1168 2009-10 2010-11 2011-12 2009-10 2010-11 2011-12
Slide 44: Shareholding Pattern
Shareholding Pattern Alembic Pharmaceuticals Limited Promoters & Promoter Group 45% Alembic Limited Public 29% 18% FI / FII / MF Total Paid up Capital 8% INR 377.03 million 188.52 million Total No. of Shareholders 50,378 As on 30th September 2012
Slide 45: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 46: Corporate Social Responsibility
Corporate Social Responsibility Rural Development Society Rural Development Society is a Social Responsibility Initiative of Alembic founded in 1979 Enhancement for self employment and income generation for economic development School, hostel and medical facilities for local villagers
Slide 47: Corporate Social Responsibility
Corporate Social Responsibility Environment Alembic believes in clean and green chemistry Zero discharge facilities comprising of state-of-the-art aeration system, ultra filtration and reverse osmosis plant, evaporation and incineration plant Dedicated scrubbing system for process gas emissions
Slide 48: Alembic Pharmaceuticals Limited
For updates and specific queries, please visit: www.alembic-india.com or feel free to contact Mitanshu Shah Tel.: 0265 - 300 7630 • Fax: 0265 - 228 2506 mitanshu.shah@alembic.co.in Alembic Pharmaceuticals Limited Alembic Road, Vadodara 390 003, India .Tel.: 0265 – 300 7000
Slide 49: Thank You
An, Touching Lives over 10> Thank You
Alembic Pharmaceuticals — Q2 FY2012-13 Earnings Presentation on 6ix